跳至主要内容
临床试验/NL-OMON51824
NL-OMON51824尚未招募不适用

Glucose metabolism in brain tumours: comparing glucoCEST MRI with [18F]FDG-PET - GlucoCEST MRI vs [18F]FDG-PET in brain tumours

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >= 18 years
  • Primary intra-axial brain tumour of any type or secondary brain tumour (brain
  • metastases) of any solid tumour
  • Signed and dated written informed consent form prior to any study-specific
  • WHO performance status of 0 or 1

排除标准

  • Glucose- and/or FDG-infusion related exclusion criteria:
  • o Uncontrolled Diabetes Mellitus type 1 or 2 (requiring fast-acting insulin)
  • o Uncontrolled tonic-clonic seizures (>1 per month despite anti-epileptic
  • Not being able to undergo contrast enhanced MR scans or [18F]FDG-PET exam (in
  • line with local protocol13):
  • o Pacemaker, mechanic heart valve, blood vessel prosthetic, stent or coil
  • incompatible with MR scanning
  • o Metal in eyes (splinters, from surgery), ears (hearing aid) or on the body
  • where it cannot be removed (e.g. insulin pump, piercings)
  • o Dental prosthesis with magnetic system
  • o Breastfeeding
  • o Pregnancy
  • o Claustrophobia
  • o Known anaphylactic reaction to [18F]FDG or gadolinium-based contrast agents
  • Severe blood iron deficiency (with haemoglobin concentration <6.0mmol/L)
  • History of severe renal disease/renal transplant, or an eGFR (MDRD)
  • <30mL/min/1,73m2
  • Has any medication that decreases the chances of obtaining reliable data and
  • achieving the study objectives
  • History of somatic or psychiatric disease/condition that may interfere with
  • the objectives and assessments of the study

研究者

相似试验

Glucose metabolism in brain tumours: comparing... | 临床试验